EXEL beats on Q2 earnings but misses revenues as lower collaboration income offsets strong Cabometyx sales growth.

Exelixis (EXEL) delivered earnings and revenue surprises of +15.38% and -1.84%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?